Cerebral Response to Sustained Hypoxia
大脑对持续缺氧的反应
基本信息
- 批准号:7437279
- 负责人:
- 金额:$ 42.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-06-15 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcetazolamideAcuteAddressAltitudeAltitude SicknessAnatomyBiological ModelsBlood VolumeBrainBrain EdemaCarbon DioxideCarbonic Anhydrase InhibitorsCardiacCerebral HypoxiaCerebrovascular CirculationCerebrumChronicClinicalConditionDataDevelopmentDiseaseEdemaEnvironmental air flowExposure toFailureFigs - dietaryFunctional Magnetic Resonance ImagingGenerationsGenetic TranscriptionGoalsHomeostasisHypoxiaIndividualInterventionIntracranial PressureLeadLeftLungMagnetic Resonance ImagingMeasurementMeasuresMechanicsMitochondriaModelingOutcomeOxygenPathway interactionsPatientsPhosphorylationPhysiologicalPhysiologyPrecipitating FactorsProcessProductionRangeRateResearchResearch PersonnelResistanceRiskRoleStandards of Weights and MeasuresStimulusSwellingSystemTestingThinkingTimeTissuesWaterbasebrain volumecerebrovascularcohortdaydesignfeedinghemodynamicshuman subjectmathematical modelpressureprogramsrelating to nervous systemresponse
项目摘要
DESCRIPTION (provided by applicant): Our overall goal is to understand the physiological consequences of global cerebral hypoxia, and how failure of the normal homeostatic mechanisms progresses to disease. To address this, it is first necessary to define the normal physiological responses to cerebral hypoxia. Cerebral hypoxia is the outcome of many disease processes (pulmonary, cardiac, cerebrovascular), and thus to investigate cerebral homeostasis mechanisms to hypoxia per se, it is important to examine them in isolation from potentially coexistent multi-system disease. In this proposal we use altitude-induced hypoxia (Acute Mountain Sickness - AMS) as a model system of isolated sustained hypoxia to study the normal physiological response mechanisms. This proposal draws hypotheses from traditional high altitude research and from functional MRI studies of cerebral physiology. We will experimentally test these existing models to explain the progression from hypoxic exposure to cerebral disease. Our specific aims are to measure the normal cerebral physiological response to acute (<6 hrs), short-term (2 days) and sustained (7 days) hypoxia (PIO2 = 90 Torr) in healthy individuals, and define the time-dependent physiologic response to hypoxia. Using MRI measurements of cerebral physiology (i.e. changes in CBF, CMRO2, CSF volume & edema) we will experimentally test individual components of the models. To systematically assess the time-course of the normal physiological responses, these measurements will be made over a range of acute and sustained hypoxic exposure. Measurements will be made in the same cohort of human subjects (encompassing AMS-susceptible andAMS-resistant individuals). These studies will provide a comprehensive picture of the cerebral physiological responses to hypoxia, and why some individuals are better able to acclimatize to low oxygen levels-we will establish a basis for understanding why patients with disease respond differently to hypoxia. Designing appropriate clinical interventions to treat chronic cerebral hypoxic decline hinges on such a comprehensive understanding.
描述(由申请人提供):我们的总体目标是了解全脑缺氧的生理后果,以及正常稳态机制的失败如何进展为疾病。为了解决这个问题,首先有必要定义对脑缺氧的正常生理反应。脑缺氧是许多疾病过程(肺、心脏、脑血管)的结果,因此为了研究缺氧本身的脑稳态机制,重要的是将它们与潜在共存的多系统疾病分开进行检查。在本提案中,我们使用高原引起的缺氧(急性高山病 - AMS)作为孤立持续缺氧的模型系统来研究正常的生理反应机制。该提议从传统的高海拔研究和脑生理学的功能性 MRI 研究中得出了假设。我们将通过实验测试这些现有模型,以解释从缺氧暴露到脑部疾病的进展。我们的具体目标是测量健康个体对急性(<6 小时)、短期(2 天)和持续(7 天)缺氧 (PIO2 = 90 Torr) 的正常脑生理反应,并定义时间依赖性生理反应对缺氧的反应。使用脑生理学的 MRI 测量(即 CBF、CMRO2、CSF 体积和水肿的变化),我们将通过实验测试模型的各个组成部分。为了系统地评估正常生理反应的时间进程,这些测量将在一系列急性和持续的缺氧暴露下进行。测量将在同一组人类受试者中进行(包括 AMS 易感者和 AMS 抵抗者)。这些研究将提供大脑对缺氧的生理反应的全面了解,以及为什么有些人能够更好地适应低氧水平——我们将为理解为什么疾病患者对缺氧的反应不同奠定基础。设计适当的临床干预措施来治疗慢性脑缺氧衰退取决于这种全面的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID DUBOWITZ其他文献
DAVID DUBOWITZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID DUBOWITZ', 18)}}的其他基金
Cerebral Diffusion: A new approach to sleep disorders
脑扩散:治疗睡眠障碍的新方法
- 批准号:
9372571 - 财政年份:2017
- 资助金额:
$ 42.53万 - 项目类别:
Hemodynamic and Metabolic Coupling in Migraine
偏头痛的血流动力学和代谢耦合
- 批准号:
8624417 - 财政年份:2013
- 资助金额:
$ 42.53万 - 项目类别:
Hemodynamic and Metabolic Coupling in Migraine
偏头痛的血流动力学和代谢耦合
- 批准号:
8730250 - 财政年份:2013
- 资助金额:
$ 42.53万 - 项目类别:
Tissue Oxygenation and Cerebral Vulnerability to Hypoxia
组织氧合和大脑缺氧的脆弱性
- 批准号:
8303023 - 财政年份:2012
- 资助金额:
$ 42.53万 - 项目类别:
Tissue Oxygenation and Cerebral Vulnerability to Hypoxia
组织氧合和大脑缺氧的脆弱性
- 批准号:
8418707 - 财政年份:2012
- 资助金额:
$ 42.53万 - 项目类别:
相似国自然基金
乙酰唑胺对高原常住居民睡眠呼吸障碍的治疗与作用机制
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
乙酰转移酶调控MGMT增强子在胶质母细胞瘤替莫唑胺耐药中作用及分子机制研究
- 批准号:
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
乙酰唑胺负荷CT灌注成像评价大鼠C6胶质瘤恶性度和侵袭力
- 批准号:81701686
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Targeting Chemoreceptor Control of Breathing during Sleep to Mitigate Opioid-Associated Sleep Disordered Breathing
针对睡眠期间呼吸的化学感受器控制,以减轻阿片类药物相关的睡眠呼吸障碍
- 批准号:
10578662 - 财政年份:2019
- 资助金额:
$ 42.53万 - 项目类别:
Targeting Chemoreceptor Control of Breathing during Sleep to Mitigate Opioid-Associated Sleep Disordered Breathing
针对睡眠期间呼吸的化学感受器控制,以减轻阿片类药物相关的睡眠呼吸障碍
- 批准号:
10295173 - 财政年份:2019
- 资助金额:
$ 42.53万 - 项目类别:
Targeting Chemoreceptor Control of Breathing during Sleep to Mitigate Opioid-Associated Sleep Disordered Breathing
针对睡眠期间呼吸的化学感受器控制,以减轻阿片类药物相关的睡眠呼吸障碍
- 批准号:
10041688 - 财政年份:2019
- 资助金额:
$ 42.53万 - 项目类别: